Background: The purpose of this study is to determine the optimal strategy for men with newly diagnosed intermediate-risk prostate cancer by age and cardiac risk. Methods: A Markov model was calibrated to the EORTC 22991 trial, which randomly assigned men with intermediate-risk prostate cancer to radiation therapy (RT) with or without six months of hormonal therapy (HT). We compared qualityadjusted life-years (QALYs) in men age 50, 60, and 70 years by age decile and cardiac risk group. Competing risks of cardiovascular mortality were estimated from the published literature. Sensitivity analyses were used to assess the impact of varying model assumptions. Results: HT was associated with a net decrease of 0.3 to 0.4 QALYs in men with a history of myocardial infarction. However, for all other men, HT improved QALYs (range ¼ 0.4-2.6 QALYs). Younger men with fewer cardiac risk factors experienced the largest benefit from HT. In sensitivity analyses, the model was only found to be sensitive to the probability of biochemical failure. Men at low risk for biochemical failure ( 8.7% at five years) did not benefit from HT. Further, the benefits of HT did not begin to manifest until after 7.3 years of follow-up. Conclusions: The optimal choice of therapy depends upon age, cardiac risk, and disease recurrence risk. Young men with intermediate-risk prostate cancer with no cardiac risk factors benefit most from HT. Men with a history of myocardial infarction who are at very low risk for biochemical failure may be negatively impacted by the addition of HT.
increased risk of cardiovascular morbidity and/or death, particularly in men with a history of myocardial infarction (MI) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . Men with a history of MI who received HT had a nearly twofold increased risk of all-cause mortality (19) . Therefore, the potential risk of cardiac mortality may outweigh the OS benefit associated with HT. Furthermore, HT may increase the risk of MI in men without preexisting cardiovascular disease (18) , likely mediated by testosterone deficiency (30) .
Given the clinical importance of the results of the EORTC 22991 trial (17) and the absence of current evidence to guide HT treatment decision-making for intermediate-risk PC, we present a model to help guide decision-making for these patients, stratified by age and cardiac risk.
Methods
We report our methods according to the guidelines of the Society for Medical Decision Making for good research practices, model transparency, and validation (31) .
Initial Treatment and Patient Cohort
Treatment allocation was based on the EORTC 22991 trial (17) , which examined the addition of six months of HT (two injections every three months of depot of luteinizing hormonereleasing hormone agonist) to primary RT (70, 74, or 78 Gy) for mostly (75%) intermediate-risk PC. Eligibility criteria included: 1) T1b-c, with prostate-specific antigen (PSA) of 10 ng/mL or higher or Gleason score of 7 or higher, or 2) cT2a (International Union Against Cancer TNM 1997) with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA of 50 ng/mL or lower, and 3) Eastern Cooperative Oncology Group performance status of 0 to 2 (17) .
Markov Model
Our prostate Markov model has been previously described in detail (32) . Briefly, men enter the model at age 50, 60, or 70 years stratified by age decile and cardiac risk and exit at the time of death ( Figure 1A ). Cardiac risk factors were defined by an analysis of the Framingham Heart Study ( Table 1) . Patients were categorized by the number of optimal, borderline, and elevated risk factors into distinct categories: all optimal, one or more borderline risk factors but no elevated risk factors, and one or more elevated risk factors (33) .
The primary end point is quality-adjusted life expectancy. Men transition between different health states, including no evidence of disease, biochemical failure, and distant metastases ( Figure 1B ). Patients are also at risk for developing MI, impotence, genitourinary (GU) or gastrointestinal toxicity (GI). Combinations of toxicities are modeled using independent health states ( Figure 1C ). For men without a history of MI, MI risk was based on age and the number of risk factors (33) . Men who received HT had an elevated risk of developing MI and dying from MI. These risks were elevated for 1.5 years, based on the expected duration of testosterone suppression (18, 19, 34, 35) . In men who received salvage therapy with lifelong androgen deprivation, the elevated risks of developing MI and MI mortality remained elevated for life. A complete decision tree sample is shown in Supplementary Figure 1 (available online).
One-way sensitivity analyses, in which one parameter was varied while all others were held constant, were conducted around all parameters to evaluate the extent to which uncertainty and variability influenced the model results. We studied ranges corresponding to the 95% confidence interval estimates around a parameter or a range of values across published studies, whichever resulted in the largest spectrum of values. In addition, the model's follow-up period, or time horizon, was varied to determine the impact of follow-up time on the model's results. Variable thresholds for which the preferred strategy (defined by the highest gain in QALYs) shifted were identified. All analyses were conducted in TreeAge Pro version 2016 (TreeAge, Williamstown, MA).
Model Inputs
Model inputs are summarized in Table 2 . We present our new model using data on bDFS and distant metastases with and without HT as reported in the EORTC 22991 trial (17) . Data were graphically extracted from the published Kaplan-Meier curves by using a validated graphical digitizer (WebPlotDigitizer version 3.4; Ankit Rohatgi, Austin, TX). We then calibrated our transition probabilities to the EORTC data using a trial and error method (36) . The time interval from the development of distant metastases to death was derived from a large surgical experience at a center of excellence and varied on sensitivity analysis to account for recent advances that prolong survival in patients with metastatic disease (37, 38) .
Men who developed MI faced an annual estimated probability of death of 11%, which was a weighted average of mortality after ST elevation and non-ST elevation myocardial infarction in the GUSTO-IIb trial (39) . In the base case, the risk of MI in men treated with HT was assumed to be 1.27 times higher than in men who did not receive HT (18) . If men treated with HT suffered MI or if men with a history of MI were treated with HT, the risk of death due to MI was assumed to be 1.96 times higher than for men with MI not treated with HT (19) . However, in sensitivity analyses, we studied a large range of values including no elevated risk ( Table 2) . Age-specific rates of death from PC and MI were subtracted from overall agespecific death rates for men from US life tables to generate age-specific death rates from other causes (40) (41) (42) . The cycle length was one month.
Complications, Adverse Effects, and Utilities
We assumed that men would be at risk for developing treatment-related complications within five years after initial treatment and that all complications would remain stable thereafter. Men who received salvage therapy were assumed to be impotent for life. Complications include urinary incontinence, bowel disturbances, and long-term erectile dysfunction that are grade 2 or higher as defined by Common Toxicity Criteria for Adverse Events (CTCAE) version 4 (43) . Complication probabilities were based on a meta-analysis of intensitymodulated radiation therapy complications for doses of 75 to 81 Gy (44) .
A utility is a preference score for a given health state and ranges from 0 (death) to 1 (perfect health). For example, the health states of distant metastases and no evidence of disease have utility values of 0.25 and 0.81, respectively (Table 2) . On sensitivity analyses, utilities were studied to an upper limit of 1, representing the case of perfect health state equivalence. Utilities associated with prostate cancer states were based on a standard gamble in men age 60 years or older, half of whom 
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had been diagnosed with prostate cancer (45) . Utilities associated with MI were based on the Coronary Heart Disease Policy Model (46) . Because it is believed that utilities in prostate cancer are multiplicative (45), a patient's utility was the product of a patient's prostate cancer state, receipt of HT, presence of MI, and treatment complications.
Results

Model Validation and Base Case Results
The modeled bDFS with and without HT closely matched the EORTC data (Supplementary Figure 2 , available online). For example, at five years the modeled bDFS with and without HT were identical to the EORTC data (82.6% and 69.8%, respectively). Similarly, at seven years of follow-up, distant metastases developed in 7.6% and 4.3% of patients with and without HT, respectively, compared with 7.6% and 4.4% in the EORTC study. The OS and PCSM at 15 years for mean age 70 years with one risk factor who received HT were 41.5% and 9.1%, respectively; without HT, they were 37.8% and 14.2%.
HT was associated with net harm in men with a history of MI and resulted in a decrease of 0.3 to 0.4 QALYs (Table 3) . However, for all other men, HT improved QALYs. The largest magnitude of benefit with HT was in mean age 50 years with optimal cardiac risk (2.6 QALYs), and the lowest was in men age 70 years with four risk factors (0.4 QALYs). Taken together, these results suggest that: 1) omission of HT is the preferred management of men with intermediate-risk PC with a history of MI, and 2) six months of HT is associated with improvements in QALYs that become apparent with extended follow-up (longer than seven years), likely driven by reductions in DM and PCSM.
Sensitivity Analyses
A statistically significant threshold across which preferred management changed was only encountered for the probability of biochemical failure with an annual threshold of 0.017 for optimal-risk patients (Figure 2A ). Below this threshold (which corresponds to 8.7% biochemical failure at five years), omission of HT was favored, including men without a history of MI. This threshold was similar for men with elevated cardiac risk factors (Supplementary Figure 3 , available online). Varying the model's time horizon demonstrated that the benefits of HT began to emerge at follow-up period of 7.3 years. Prior to this threshold, there was no apparent HT benefit in any cohort. The magnitude of the benefit continued to increase with additional follow-up time ( Figure 2B ). Additional sensitivity analyses were performed to test key assumptions, such as the probability of developing an MI, the hazard ratios for the development of MI and risk of death with HT, and the utilities of no evidence of disease, HT, and biochemical failure. Results of these analyses for a representative cohort of men age 60 years with two elevated risk factors are summarized in Table 4 . For instance, if 0.5 utility is assumed for the no evidence of disease state, the incremental benefit of HT is reduced from 1.1 in the base case to 0.3 QALYs. While HT was still the preferred strategy in this scenario, the magnitude of benefit decreased. If 0.5 utility was assumed for patients receiving HT, QALYs were reduced by 1.1 in men treated with RT alone. This result highlights the fact that while men treated with RT and HT receive HT at treatment initiation, a much larger percentage of RT-alone patients need it for life at the time of biochemical failure. Varying the risks of MI and cardiac death had little effect on outcomes.
Discussion
The EORTC 22991 trial demonstrates a clear PC control benefit by adding HT to dose-escalated RT with regard to bDFS compared with RT alone, with 7.2 years' median follow-up (17) . While OS data are not yet mature, it is possible that with longer follow-up a survival benefit will be observed with HT, given that improvements in bDFS can result in an OS benefit (47) . It remains to be determined, however, which subgroups of patients with intermediate-risk PC benefit most from HT. This is of particular interest given the recently proposed subdivisions of intermediate-risk disease into favorable and unfavorable groups based on Gleason score pattern, PSA, and percent positive cores (48) (49) (50) (51) (52) (53) (54) . Furthermore, the presence of clinically significant comorbidity, and in particular cardiovascular disease, may offset the benefit of HT either because of the marginal benefit in a patient with limited overall life expectancy and/or a true negative interaction between cardiovascular disease and HT. Additionally, HT is associated with statistically significant adverse side effects, including fatigue and sexual dysfunction (55) . This was further demonstrated in the EORTC 22991 trial as sexual function was more severely affected in patients who received RT þ HT compared with RT alone (27.0% vs 19.4%, P ¼ 0.010) (17). 
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Given the complicated nature of patient identification and treatment selection, decision analyses can help clinicians strategize by comparing risks and benefits associated with different treatment options (56) . Therefore, we created a decision analysis to replicate outcomes of the EORTC 22992 study and to generate expected outcomes with additional follow-up after stratifying men by age and cardiovascular risk (33) . In our model, a benefit to HT was not observed until just beyond the median follow-up of the EORTC 22992 (7.2 years). This suggests that benefits of adding six months of HT to RT are expected to manifest with longer follow-up, with the exception of men with a history of MI, where no benefit was observed with lifetime follow-up. Our model also showed that the healthiest men with the longest life expectancy benefited the most from HT. For instance, the magnitude of benefit was much larger in men age 50 years with optimal risk compared with men age 70 years with four cardiac risk factors (2.6 vs 0.4 QALYs). These results can be explained by the greater competing risks of death and shorter life expectancy in older men with cardiac risk factors. When exploring ranges of values on sensitivity analyses, the results were consistent over a wide variety of assumptions. We found that HT is not likely to improve QALYs in men at low risk for biochemical failure ( 8.7% at five years). In a retrospective analysis that stratified patients treated with dose-escalated RT with or without HT into favorable intermediate-risk, marginal, and unfavorable intermediate-risk groups, the five-year bDFS for patients treated with RT alone was 94% in the favorable-risk group compared with 74% in unfavorable-risk group (48) . Therefore, our analysis suggests that men with intermediaterisk PC with a low risk of biochemical failure-similar to favorable intermediate-risk disease-achieve optimal QALYs with RT alone, regardless of the number of cardiac risk factors. Using our model to extrapolate beyond what is reported in the EORTC 22991 trial, the men most likely to benefit from HT include those with unfavorable intermediate-risk PC and up to four cardiac risk factors. Conversely, men with favorable intermediate-risk disease or those with history of MI are unlikely to benefit. Sensitivity analyses also revealed that the up-front, transient side effects from HT are negated by avoiding lifetime HT at the time of recurrence in men who received RT with HT. This should be considered during the decision-making process in candidates for HT.
Men with a history of MI have a shorter life expectancy relative to men without previous MI (57) . Therefore, in our model, harms associated with HT-including unwanted side effects and the potential increased risks of cardiac mortalityoutweigh improvements in PCSM in men with clinically significant cardiovascular disease. HT was observed to negatively impact men with a history of MI (À0.3 to À0.4 QALYs) because the reductions in QALYs from HT were more apparent in men with the shortest life expectancy. Similarly, when 0.5 utility was assumed for the no evidence of disease health state in averagerisk men in our model, the benefits of HT were reduced (1.1 vs 0.3 QALYs).
While several population-based studies have showed positive associations between HT and both the incidence of cardiovascular disease and worsened death from cardiovascular disease (18, 19, 21, 23, 25) , postrandomization analyses have produced conflicting data. While some analyses suggest increased risk of MI and lack of benefit of HT (27, 58) , others do not report an increased risk of MI and cardiovascular mortality in men with PC who received HT (59) (60) (61) . The discrepancy among these studies is perhaps explained by the fact that the prospective randomized trials did not evaluate cardiovascular outcomes in men with a documented history of MI (1) (2) (3) (4) (5) (6) (7) 62) . For example, in the meta-analysis by Nguyen et al., trials included in the analysis did not stratify by preexisting cardiovascular comorbidity (24) .
Our study is consistent with population-based analyses, which show that reductions in PC mortality from HT are offset by net harm in men with baseline cardiovascular disease (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Whether HT is necessary for favorable intermediate-risk PC will be addressed by RTOG 0815 (16) . In the absence of mature data from this trial, the current study and other retrospective series demonstrate that dose-escalated RT may be sufficient for patients with intermediate-risk PC and cardiovascular risk factors (48) (49) (50) (51) (52) (53) .
This study has several limitations. First, the underlying risk of MI development and mortality was derived from the Framingham Heart Study, which was undertaken prior to introduction of sophisticated cardiovascular imaging and percutaneous coronary intervention. The present study suggests that we should incorporate a more sophisticated cardiac risk stratification scheme that includes noninvasive anatomic and physiologic assessment of coronary artery disease.
Second, we did not model four months of HT, an option for men with intermediate-risk PC based on the RTOG 9910 randomized trial (63) . However, this trial did not incorporate dose escalation, and it may be underpowered in men with unfavorable intermediate-risk PC who might benefit from more than four months of HT (64) . Specifically, the proportion of men in RTOG 9910 with favorable intermediate-risk PC, a subgroup of intermediate-risk PC where HT may not be necessary to reduce the risk of PCSM, is unknown.
Third, there is uncertainty inherent to quality of life estimates. In our study, there were no thresholds found for health state utilities. The utility estimates were based on a widely cited source of 162 men age 60 years or older (52% of whom had been diagnosed with prostate cancer) who were highly motivated volunteers. Finally, a Markov model is not a substitute for a prospective randomized controlled trial. A randomized trial comparing HT þ RT to RT alone in patients stratified by both favorable and unfavorable intermediate-PC risk and cardiac risk is the optimal method of assessing the impact of HT on cardiovascular outcomes.
In conclusion, we found that most men with intermediate-risk PC are expected to benefit from HT if they survive beyond seven years. However, patients with multiple cardiac risk factors may have a decrement in survival with HT. In the absence of randomized data, the current study suggests that younger patients with no cardiac risk factors should receive RT with HT. However, patients at very low risk of biochemical failure or who have a history of MI should be treated with RT alone regardless of cardiac risk. Figure 2 . One-way sensitivity analyses. A) The probability of biochemical failure is varied in men with optimal cardiac risk. An annual probability threshold value of 0.017 is encountered. Radiation therapy is the preferred strategy if the annual probability of biochemical failure is less than 0.017, but above this threshold RT þ HT is preferred. B) The model's time horizon, or follow-up period, is varied from 40 months (3.3 years) to 168 months (14 years). A threshold is encountered at 87.6 months (7.3 years), after which the benefit of adding hormonal therapy begins to emerge. EV ¼ expected value; GI ¼ gastrointestinal; GU ¼ genitourinary; HT ¼ hormonal therapy; MI ¼ myocardial infarction.
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